Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Sees Large Decrease in Short Interest

Inovio Pharmaceuticals, Inc. (NASDAQ:INOGet Rating) was the target of a significant drop in short interest in May. As of May 31st, there was short interest totalling 34,410,000 shares, a drop of 20.5% from the May 15th total of 43,310,000 shares. Based on an average daily trading volume, of 5,830,000 shares, the days-to-cover ratio is presently 5.9 days.

INO stock traded down $0.02 during trading hours on Thursday, hitting $1.51. The company’s stock had a trading volume of 191,626 shares, compared to its average volume of 5,344,951. The company has a quick ratio of 6.74, a current ratio of 6.74 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $344.71 million, a PE ratio of -0.97 and a beta of 0.82. Inovio Pharmaceuticals has a 12 month low of $1.40 and a 12 month high of $9.96. The stock has a 50 day moving average price of $2.35 and a two-hundred day moving average price of $3.68.

Inovio Pharmaceuticals (NASDAQ:INOGet Rating) last announced its earnings results on Tuesday, May 10th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.08). Inovio Pharmaceuticals had a negative return on equity of 76.48% and a negative net margin of 20,479.29%. The firm had revenue of $0.20 million for the quarter, compared to analyst estimates of $0.66 million. During the same quarter last year, the business posted ($0.27) EPS. The firm’s revenue was down 46.4% compared to the same quarter last year. Sell-side analysts expect that Inovio Pharmaceuticals will post -1.19 earnings per share for the current year.

Several institutional investors and hedge funds have recently bought and sold shares of INO. Wells Fargo & Company MN lifted its stake in Inovio Pharmaceuticals by 5.8% during the 2nd quarter. Wells Fargo & Company MN now owns 126,883 shares of the biopharmaceutical company’s stock valued at $1,175,000 after acquiring an additional 6,971 shares during the period. Morgan Stanley increased its stake in Inovio Pharmaceuticals by 185.6% in the second quarter. Morgan Stanley now owns 830,060 shares of the biopharmaceutical company’s stock valued at $7,694,000 after purchasing an additional 539,469 shares during the last quarter. GSA Capital Partners LLP boosted its position in shares of Inovio Pharmaceuticals by 43.0% in the third quarter. GSA Capital Partners LLP now owns 33,894 shares of the biopharmaceutical company’s stock worth $243,000 after buying an additional 10,188 shares during the period. Dimensional Fund Advisors LP boosted its stake in Inovio Pharmaceuticals by 50.1% during the 3rd quarter. Dimensional Fund Advisors LP now owns 31,301 shares of the biopharmaceutical company’s stock valued at $224,000 after purchasing an additional 10,444 shares in the last quarter. Finally, Invesco Ltd. raised its holdings in shares of Inovio Pharmaceuticals by 9.9% during the third quarter. Invesco Ltd. now owns 92,556 shares of the biopharmaceutical company’s stock worth $662,000 after acquiring an additional 8,372 shares in the last quarter. Institutional investors own 43.28% of the company’s stock.

Several brokerages recently weighed in on INO. Cantor Fitzgerald dropped their target price on Inovio Pharmaceuticals from $6.00 to $3.00 in a report on Wednesday, May 11th. Royal Bank of Canada decreased their price target on Inovio Pharmaceuticals from $6.00 to $5.00 and set a “sector perform” rating on the stock in a report on Wednesday, March 2nd. Oppenheimer lowered Inovio Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Wednesday, May 11th. Finally, StockNews.com raised shares of Inovio Pharmaceuticals to a “sell” rating in a report on Monday, May 23rd. One research analyst has rated the stock with a sell rating and five have given a hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $11.80.

Inovio Pharmaceuticals Company Profile (Get Rating)

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.

Read More

Want More Great Investing Ideas?

Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.